Generic drug of the therapeutic class: Cardiology and angiology
Active ingredients: Nifedipine
laboratory: Bayer Healthcare
Sustained release tablet
Box of 30
Dosage ADALATE LP 20 mg Sustained Release Tablet Box of 30
1 tablet twice a day to swallow without chewing, with a little liquid.
It is recommended that treatment be initiated with caution in patients who may experience an overreaction to nifedipine.
If therapy is discontinued, doses should be reduced gradually.
The recommended interval between 2 doses of ADALATE LP 20 mg is approximately 12 hours and should be at least 4 hours.
Children and adolescents
The safety and efficacy of ADALATE LP 20 mg tablets have not been studied in children under 18 years of age. Currently available data on the use of nifedipine in arterial hypertension are described in section Pharmacodynamic properties .
As the bioavailability of nifedipine is increased in the elderly, ADALATE LP 20 mg tablets should be administered with caution in this population.
Due to its hepatic metabolism, nifedipine should be administered under supervision in patients with hepatic impairment. In addition, there are no clinical data in patients with severe hepatic impairment.
There are no clinical data in renally impaired patients. ADALATE LP 20 mg should be used with caution in these patients.
This medicine should not be used in the following cases:
· Known hypersensitivity to nifedipine, or to any of the excipients,
· Myocardial infarction less than 1 month old,
· Unstable angina (see section Warnings and precautions for use ),
· Cardiovascular shock (see section Warnings and precautions for use ),
· In combination with diltiazem (see section Interactions with other medicinal products and other forms of interaction )
This medication is generally not recommended during the first trimester of pregnancy (see section Pregnancy and breast-feeding ).
Adalate LP Adverse Effects
The risk of hypotension and / or decompensation of heart failure should be given special attention.
The adverse events reported in the placebo-controlled studies evaluating the effect of nifedipine are presented below by CIOMS III frequency category (clinical trial database: nifedipine n = 2661; placebo n = 1, 486; as of February 22, 2006 and ACTION study: nifedipine n = 3825; placebo n = 3840).
Adverse events considered "frequent" were observed with an incidence of less than 3%, with the exception of edema (9.9%) and headache (3.9%).
The frequency of adverse reactions reported with products containing nifedipine is summarized in the table below. In each frequency group, side effects are presented in descending order of safety.
The frequencies are defined as follows:
· Frequent: ≥ 1/100 to <1/10
· Uncommon: ≥ 1/1000 to <1/100
· Rare: ≥ 1/10 000 to <1/1000
Adverse reactions identified only during post-marketing surveillance and for which the frequency can not be expressed are classified as "unknown frequency".
Class-organ system (MedDRA)
Blood and lymphatic system disorders
Immune system disorders
Allergic reaction, Quincke's edema
Anaphylactic / anaphylactoid reaction
Metabolism and nutrition disorders
Nervous system disorders
Vision disorders (mainly blurred vision or decreased vision)
Chest pain (angina)
Respiratory, thoracic and mediastinal disorders
Gastrointestinal and abdominal pain
Esophagitis associated with gastroesophageal sphincter insufficiency
Transient increase in hepatic transaminases or bilirubin
Skin and subcutaneous tissue disorders
Toxic epidermal necrolysis
Musculoskeletal and systemic disorders
Inflammatory swelling of the joints
Renal and urinary disorders
Reproductive and breast disorders
General disorders and administration site conditions
Asthenia or Fatigue,
1 = potentially life-threatening
In dialysis patients with malignant hypertension and hypovolemia, vasodilation may result in significant blood pressure drop.
Reporting of suspected adverse reactions
The reporting of suspected adverse reactions after authorization of the drug is important. It allows continuous monitoring of the benefit / risk ratio of the drug. Healthcare professionals declare any suspected adverse reaction via the national reporting system: National Agency for the Safety of Medicines and Health Products (Ansm) and the network of Regional Pharmacovigilance Centers - Website: www.ansm.sante.fr